###### Strengths and limitations of this study

-   This nationwide cohort study based on the French healthcare databases is the largest study to date to assess the association between antiepileptic drug (AED) exposure during pregnancy and neurodevelopmental outcomes in the offspring.

-   This study investigated a wide range of AEDs, including some drugs for which little or no information is available in the literature.

-   Although residual confounding by unmeasured covariates cannot be excluded, the choice of lamotrigine as the reference group and the sensitivity analysis restricted to women considered to be treated for epilepsy should mitigate confounding.

-   The maximum length of follow-up was 6 years, allowing only early diagnoses of neurodevelopmental disorders to be identified.

Introduction {#s1}
============

Antiepileptic drugs (AEDs) are commonly prescribed during pregnancy to treat epilepsy and various other conditions, such as neuropathic pain syndromes, psychiatric disorders and chronic migraine[@R1]: between 0.4% and 0.7% of women are exposed to AEDs during pregnancy in Europe,[@R2] while this prevalence is as high as 2% in the US.[@R4]

Some of these AEDs are known to be teratogens.[@R5] Of all AEDs, prenatal exposure to valproic acid has been most clearly associated with poor neurodevelopmental outcomes,[@R6] which led the US Food and Drug Administration to issue a warning in 2011[@R7] and stringent guidance in 2013 for clinicians prescribing valproic acid to pregnant women or women of childbearing potential.[@R8] The European Medicines Agency also strengthened warnings on the use of valproate-containing medicines in women and girls in 2014[@R9] and issued a ban in 2018 on the use of such medicines during pregnancy for migraine or bipolar disorder, and for epilepsy except when no other effective treatment is available.[@R10]

Lamotrigine has generally been associated with favourable neurodevelopmental outcomes.[@R6] Discordant but mainly reassuring data have been published for carbamazepine, while evidence for levetiracetam and topiramate remains limited and almost no information is available concerning the other AEDs, particularly clonazepam, oxcarbazepine, gabapentin and pregabalin.[@R6] Furthermore, most of the studies conducted to date have been based on small sample sizes and may be prone to selection bias.

We therefore conducted a large-scale nationwide cohort study using the French healthcare databases to assess various early neurodevelopmental outcomes among children prenatally exposed to monotherapy with individual AEDs compared with lamotrigine-exposed children.

Methods {#s2}
=======

Study design and data sources {#s2-1}
-----------------------------

The French national health insurance database (Système national d'information interrégimes de l'Assurance maladie (SNIIRAM)) and the French hospital discharge database (Programme de médicalisation des systèmes d\'information (PMSI)) linked by a unique patient identifier were used to conduct this nationwide population-based cohort study.[@R11]

The SNIIRAM database contains all individualised and anonymous healthcare claims reimbursed by French National Health Insurance, in particular all dispensed drugs and medical procedures in the outpatient setting. The SNIIRAM database also collects patient data such as age, gender, vital status and eligibility for complementary universal health insurance (CMU-C), which provides free access to healthcare for low-income people.[@R12] Eligibility for 100% health insurance coverage for serious and costly long-term diseases (LTD) is also recorded in the SNIIRAM database.

The PMSI database provides detailed medical information on all admissions to public and private hospitals in France, including primary, related and associated discharge diagnoses, medical procedures and data related to pregnancy such as gestational ages and birth weights.

Drugs are coded according to the Anatomical Therapeutic Chemical (ATC) classification and medical procedures are coded according to the French medical classification of clinical procedures (Classification commune des actes médicaux (CCAM)). LTD and hospital discharge diagnoses are coded according to the International Classification of Diseases, 10th Revision (ICD-10).

This linkage has previously been used to conduct epidemiological studies in pregnancy research.[@R3]

Study population {#s2-2}
----------------

All live births between January 2011 and December 2014 were eligible for inclusion. These live births were identified by using a published algorithm based on discharge diagnoses and medical procedures indicative of completion of pregnancy.[@R3]

The mother had to be enrolled in the national health insurance general scheme (75% of the French population), during the penultimate year before pregnancy. Pregnancies that could not be linked to neonatal data and twin pregnancies were excluded, as well as pregnancies for which the child had no valid identifier allowing follow-up and pregnancies for which gestational ages or birth weights were not available. Children with a hospital discharge diagnosis of brain malformation documented at birth were also excluded (see [online supplementary table 1](#SP1){ref-type="supplementary-material"} for ICD-10 codes). For each woman, only the first birth occurring during the study period was considered.
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Finally, only pregnancies exposed to AED monotherapy were included in the study population.

These exclusion criteria are reported in the study population flow chart ([figure 1](#F1){ref-type="fig"}).

![Inclusion flow chart. AED, antiepileptic drug.](bmjopen-2019-034829f01){#F1}

Patient and public involvement {#s2-3}
------------------------------

Patients or the public were not involved in the design and the conduct of the study.

Exposure {#s2-4}
--------

All AEDs were studied ([online supplementary table 2](#SP1){ref-type="supplementary-material"}). Women were considered to be exposed during the 30 days following dispensing of an AED, as AED prescriptions are dispensed with a 30-day supply in France. Women were therefore exposed during pregnancy when an AED had been dispensed between 30 days before the beginning of pregnancy and the end of pregnancy. Monotherapy was defined as the absence of any other AED dispensed during the same period. Results related to AEDs rarely used as monotherapy during pregnancy (\<100 exposed pregnancies) were not reported. The reference group included pregnant women exposed to lamotrigine monotherapy for the following reason: active-comparator designs minimise confounding by indication compared with the use of an unexposed control group[@R16]; lamotrigine is the most commonly used AED in France for the treatment of epilepsy; prenatal exposure to lamotrigine has been mostly shown to be associated with favourable neurodevelopmental outcomes; comparing all individual AEDs with lamotrigine addresses a clinically relevant question: which is the safest AED?

Mean daily doses were calculated by dividing cumulative doses by the number of days covered. Cumulative doses were assessed by equally distributing the dose of AED dispensed over the 30 days following dispensing and then by adding these daily doses overlapping with the pregnancy period. The number of days covered was defined as the sum of the 30-day periods of exposure corresponding to each refill minus the number of days of overlap between two consecutive refills. Only the days overlapping with the pregnancy period were taken into account.

Outcomes {#s2-5}
--------

Four outcomes were considered, based on the literature and on their availability in the French healthcare databases. The primary outcomes were hospitalisation or LTD for neurodevelopmental disorders (ICD-10 diagnosis codes F70--F98), and for two specific subcategories: pervasive developmental disorders (F84) and mental retardation (F70--F79). The secondary outcome was 'visits to a speech therapist', as a proxy for communication-related disorders.

Follow-up {#s2-6}
---------

Children were followed from birth until any of the predefined outcomes, loss to follow-up (\>1 year with no reimbursement), death from any cause or end of the study period defined as the 31 December 2016, whichever came first.

Covariates {#s2-7}
----------

Potential confounders related to the mother and considered in this study included sociodemographic covariates (maternal age at birth and eligibility for CMU-C), as well as comedications and comorbidities. Comedications included (1) preconception folic acid supplementation, defined as at least one dispensing between 1 month before pregnancy and 3 months after the start of pregnancy, (2) exposure to selective serotonin reuptake inhibitors (SSRIs) during pregnancy, (3) exposure to antipsychotics in the year before pregnancy, (4) a proxy for severity of mental disorders (the number of fifth-level ATC classes of psychiatric medications dispensed in the year before pregnancy). History of mental and behavioural disorders not related to alcohol or smoking, which was identified by using hospital discharge and LTD diagnoses, was also considered to be potential confounder. Alcohol intake and smoking were not directly available in the databases and proxies were calculated using modified versions of previously published algorithms.[@R17] These proxies were constructed on the basis of hospital discharge diagnoses, LTD diagnoses and the child's hospital discharge diagnoses at birth. We also used specific drug reimbursements for alcohol intake and nicotine replacement therapy reimbursements for smoking. Potential confounders related to the child and considered in this study were gender, gestational age and birth weight.

All drugs and ICD-10 codes related to hospital discharge and LTD diagnoses used to define covariates are presented in [online supplementary table 1](#SP1){ref-type="supplementary-material"}.

Statistical analyses {#s2-8}
--------------------

Baseline covariates were compared between pregnancies exposed to each AED studied and lamotrigine-exposed pregnancies using χ^2^ tests. Number of events, crude event rates and crude incidence rate ratios (IRRs) were calculated. Potential confounders were controlled for by performing inverse probability of treatment weighting (IPTW) analyses using the propensity score. These analyses were conducted separately according to the type of AED. Propensity scores were determined by using logistic regression models including the covariates listed above, with maternal age as a categorical variable (≤25 years, 25--30, 30--35 and ≥35). Weights were trimmed at the 0.1 and 99.9 percentiles. Absolute standardised differences were calculated to assess the balance in baseline covariates before and after weighting. Groups were considered to be balanced when standardised differences were \<0.1.[@R18] Cox models with robust sandwich estimates were used to calculate HRs and their 95% CIs.

As AEDs can be prescribed for a wide range of medical conditions other than epilepsy, a first sensitivity analysis in which the study population was restricted to women considered to be treated for epilepsy (see [online supplementary table 1](#SP1){ref-type="supplementary-material"} for definition) was conducted. In this sensitivity analysis, HRs were further adjusted for hospitalisation (primary and related diagnoses only) for epilepsy during pregnancy. A second sensitivity analysis, requiring at least one dispensing during pregnancy to consider a woman to be exposed, was also conducted to account for possible misclassification of exposure at the beginning of pregnancy. In a third sensitivity analysis, two other propensity scores were calculated: one excluding proxies for alcohol intake and smoking and another one excluding gestational age and birth weight.

Data extraction and statistical analysis were performed by using SAS Enterprise Guide V.4.3 software (SAS Institute, Cary, North Carolina, USA). Graphics were performed by using R V.3.5 statistical software.

Results {#s3}
=======

Main analysis {#s3-1}
-------------

From a total of 1 721 990 births satisfying all inclusion and exclusion criteria, 9034 children were prenatally exposed to AED monotherapy ([figure 1](#F1){ref-type="fig"}), 32 (0.4%) of whom were censored at death and 1224 (13.5%) were lost to follow-up. The median follow-up was 3.7 years (IQR, 2.7--4.7 years). Of these 9034 children, 2916 were exposed to lamotrigine, 1627 were exposed to pregabalin, 1246 were exposed to clonazepam, 991 were exposed to valproic acid, 621 were exposed to levetiracetam, 502 were exposed to carbamazepine, 477 were exposed to topiramate, 378 were exposed to gabapentin and 143 were exposed to oxcarbazepine ([table 1](#T1){ref-type="table"}). A total of 133 children were exposed to another AED monotherapy, including phenobarbital (n=84), phenytoin (n=13), lacosamide (n=9), zonisamide (n=8), ethosuximide (n=7) and vigabatrin (n=6). The median follow-up ranged from 3.3 to 4.0 years across all AEDs except clonazepam (4.8 years).

###### 

Baseline characteristics according to AED use during pregnancy

                                                Lamotrigine        Carbamazepine      Clonazepam         Gabapentin         Levetiracetam                                                          
  --------------------------------------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------ ------------ ------------ ------------ --------
  Number of exposed pregnancies                 2916               502                1246               378                621                                                                    
  Median follow-up (years) (IQR)                3.5 (2.7 to 4.5)   3.8 (2.8 to 4.7)   4.8 (4.1 to 5.3)   3.4 (2.5 to 4.3)   3.4 (2.6 to 4.4)                                                       
  Maternal age at birth (years)                 \<25               431 (14.8)         51 (10.2)          \*\*\*             118 (9.5)          \*\*\*       32 (8.5)     \*\*\*       119 (19.2)   \*\*
  25--30                                        927 (31.8)         119 (23.7)         302 (24.2)         90 (23.8)          212 (34.1)                                                             
  30--35                                        980 (33.6)         168 (33.5)         380 (30.5)         125 (33.1)         181 (29.1)                                                             
  ≥35                                           578 (19.8)         164 (32.7)         446 (35.8)         131 (34.7)         109 (17.6)                                                             
  Eligibility for CMU-C                         461 (15.8)         98 (19.5)          \*                 303 (24.3)         \*\*\*             82 (21.7)    \*\*         134 (21.6)   \*\*\*       
  History of mental and behavioural disorders   368 (12.6)         104 (20.7)         \*\*\*             216 (17.3)         \*\*\*             43 (11.4)    NS           51 (8.2)     \*\*         
  Proxy for alcohol intake                      35 (1.2)           7 (1.4)            NS                 35 (2.8)           \*\*\*             6 (1.6)      NS           13 (2.1)     NS           
  Proxy for smoking                             311 (10.7)         59 (11.8)          NS                 165 (13.2)         \*                 66 (17.5)    \*\*\*       69 (11.1)    NS           
  Folic acid supplementation                    2026 (69.5)        281 (56.0)         \*\*\*             360 (28.9)         \*\*\*             139 (36.8)   \*\*\*       396 (63.8)   \*\*         
  SSRIs during pregnancy                        210 (7.2)          42 (8.4)           NS                 201 (16.1)         \*\*\*             42 (11.1)    \*\*         23 (3.7)     \*\*         
  History of antipsychotic use                  227 (7.8)          64 (12.7)          \*\*\*             123 (9.9)          \*                 24 (6.3)     NS           15 (2.4)     \*\*\*       
  Number of psychiatric medications†            0                  1641 (56.3)        265 (52.8)         \*                 492 (39.5)         \*\*\*       157 (41.5)   \*\*\*       366 (58.9)   NS
  1                                             669 (22.9)         107 (21.3)         283 (22.7)         91 (24.1)          138 (22.2)                                                             
  2                                             258 (8.8)          42 (8.4)           149 (12.0)         49 (13.0)          54 (8.7)                                                               
  3--4                                          211 (7.2)          52 (10.4)          183 (14.7)         54 (14.3)          39 (6.3)                                                               
  ≥5                                            137 (4.7)          36 (7.2)           139 (11.2)         27 (7.1)           24 (3.9)                                                               
  Gestational age (weeks after LMP)             \<32               11 (0.4)           3 (0.6)            NS                 10 (0.8)           NS           2 (0.5)      \*\*\*       7 (1.1)      NS
  32--35                                        42 (1.4)           8 (1.6)            28 (2.2)           23 (6.1)           11 (1.8)                                                               
  35--37                                        129 (4.4)          14 (2.8)           55 (4.4)           21 (5.6)           33 (5.3)                                                               
  ≥37                                           2734 (93.8)        477 (95.0)         1153 (92.5)        332 (87.8)         570 (91.8)                                                             
  Gender (male)                                 1524 (52.3)        265 (52.8)         NS                 597 (47.9)         \*                 206 (54.5)   NS           292 (47.0)   \*           
  Birth weight                                  \<2500             179 (6.1)          35 (7.0)           NS                 105 (8.4)          \*           47 (12.4)    \*\*\*       60 (9.7)     \*\*\*
  2500--3000                                    630 (21.6)         110 (21.9)         278 (22.3)         73 (19.3)          152 (24.5)                                                             
  3000--3500                                    1196 (41.0)        182 (36.3)         485 (38.9)         140 (37.0)         251 (40.4)                                                             
  ≥3500                                         911 (31.2)         175 (34.9)         378 (30.3)         118 (31.2)         158 (25.4)                                                             

                                                Oxcarbazepine      Pregabalin         Topiramate         Valproic acid                                                          
  --------------------------------------------- ------------------ ------------------ ------------------ ------------------ ------------ ------------ ------------ ------------ --------
  Number of exposed pregnancies                 143                1627               477                991                                                                    
  Median follow-up (years) (IQR)                4.0 (2.7 to 4.8)   3.3 (2.5 to 4.3)   3.6 (2.6 to 4.6)   3.9 (2.8 to 4.8)                                                       
  Maternal age at birth (years)                 \<25               23 (16.1)          NS                 139 (8.5)          \*\*\*       66 (13.8)    NS           137 (13.8)   \*\*\*
  25--30                                        32 (22.4)          414 (25.4)         144 (30.2)         259 (26.1)                                                             
  30--35                                        52 (36.4)          495 (30.4)         153 (32.1)         310 (31.3)                                                             
  ≥35                                           36 (25.2)          579 (35.6)         114 (23.9)         285 (28.8)                                                             
  Eligibility for CMU-C                         36 (25.2)          \*\*               404 (24.8)         \*\*\*             79 (16.6)    NS           311 (31.4)   \*\*\*       
  History of mental and behavioural disorders   36 (25.2)          \*\*\*             169 (10.4)         \*                 54 (11.3)    NS           96 (9.7)     \*           
  Proxy for alcohol intake                      1 (0.7)            NS                 21 (1.3)           NS                 7 (1.5)      NS           22 (2.2)     \*           
  Proxy for smoking                             13 (9.1)           NS                 257 (15.8)         \*\*\*             43 (9.0)     NS           136 (13.7)   \*\*         
  Folic acid supplementation                    89 (62.2)          NS                 440 (27.0)         \*\*\*             179 (37.5)   \*\*\*       525 (53.0)   \*\*\*       
  SSRIs during pregnancy                        22 (15.4)          \*\*\*             172 (10.6)         \*\*\*             55 (11.5)    \*\*         33 (3.3)     \*\*\*       
  History of antipsychotic use                  31 (21.7)          \*\*\*             79 (4.9)           \*\*\*             30 (6.3)     NS           49 (4.9)     \*\*         
  Number of psychiatric medications†            0                  65 (45.5)          \*\*\*             701 (43.1)         \*\*\*       217 (45.5)   \*\*\*       653 (65.9)   \*\*\*
  1                                             33 (23.1)          355 (21.8)         92 (19.3)          180 (18.2)                                                             
  2                                             14 (9.8)           227 (14.0)         69 (14.5)          67 (6.8)                                                               
  3--4                                          9 (6.3)            216 (13.3)         68 (14.3)          45 (4.5)                                                               
  ≥5                                            22 (15.4)          128 (7.9)          31 (6.5)           46 (4.6)                                                               
  Gestational age (weeks after LMP)             \<32               1 (0.7)            NS                 12 (0.7)           \*           7 (1.5)      \*           7 (0.7)      NS
  32--35                                        3 (2.1)            37 (2.3)           10 (2.1)           19 (1.9)                                                               
  35--37                                        6 (4.2)            61 (3.7)           19 (4.0)           45 (4.5)                                                               
  ≥37                                           133 (93.0)         1517 (93.2)        441 (92.5)         920 (92.8)                                                             
  Gender (male)                                 65 (45.5)          NS                 847 (52.1)         NS                 254 (53.2)   NS           496 (50.1)   NS           
  Birth weight                                  \<2500             12 (8.4)           NS                 118 (7.3)          NS           32 (6.7)     NS           88 (8.9)     \*
  2500--3000                                    30 (21.0)          324 (19.9)         90 (18.9)          227 (22.9)                                                             
  3000--3500                                    60 (42.0)          630 (38.7)         203 (42.6)         389 (39.3)                                                             
  ≥3500                                         41 (28.7)          555 (34.1)         152 (31.9)         287 (29.0)                                                             

Figures are N (%).

\*P\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.

†Number of fifth-level ATC classes of psychiatric medications to whom mothers were exposed in the year before pregnancy.

AED, antiepileptic drug; ATC, Anatomical Therapeutic Chemical; CMU- C, complementary universal health insurance for low-income people; IQR, interquartile range; LMP, last menstrual period; NS, not significant; SSRIs, selective serotonin reuptake inhibitors.

[Table 1](#T1){ref-type="table"} also reports baseline patient characteristics according to the type of AED prior to IPTW, showing some significant differences between the various AEDs studied and lamotrigine. Before weighting, across all variables included in the propensity score and all AEDs studied, the absolute standardised differences ranged from 0.00 to 0.94. After weighting, all standardised differences were \<0.1, indicating a good balance between treatment groups ([figure 2](#F2){ref-type="fig"}).

![Differences in baseline covariates between children exposed to lamotrigine (reference group) and children exposed to the other AEDs studied before (grey dots) and after IPTW (black dots). AED, antiepileptic drug; IPTW, inverse probability of treatment weighting; CMU-C, complementary universal health insurance; n psy. medications, number of Anatomical Therapeutic Chemical classes of psychiatric medications.](bmjopen-2019-034829f02){#F2}

[Table 2](#T2){ref-type="table"} presents the number of events, crude event rates, IRRs and adjusted HRs for the four outcomes and each of the AEDs studied. Compared with prenatal exposure to lamotrigine, prenatal exposures to all of the AEDs studied, excluding valproic acid, were not found to be associated with an increased risk of any of the four outcomes investigated. By contrast, valproic acid was associated with an increased risk of visits to a speech therapist (HR=1.5, 95% CI (1.1 to 1.9)) and neurodevelopmental disorders (HR=2.7 (1.8 to 4.0)), particularly pervasive developmental disorders (HR=4.4 (2.1 to 9.3)) and mental retardation (HR=3.1 (1.5 to 6.2)), compared with lamotrigine.

###### 

Number of events, crude event rates (per 1000), crude IRRs and adjusted HRs for the four outcomes and each of the AEDs studied---main analysis

                                      Events   Crude event rates   IRR                    HR (95% CI)
  ----------------------------------- -------- ------------------- ---------------------- ----------------------
  Neurodevelopmental disorders                                                            
   Lamotrigine                        51       4.9                                         
   Carbamazepine                      13       7.0                 1.4 (0.8 to 2.6)       1.2 (0.6 to 2.2)
   Clonazepam                         28       5.1                 1.0 (0.6 to 1.6)       0.6 (0.4 to 1.1)
   Gabapentin                         4        3.1                 0.6 (0.2 to 1.7)       0.4 (0.1 to 1.3)
   Levetiracetam                      8        3.7                 0.8 (0.4 to 1.6)       0.7 (0.3 to 1.5)
   Oxcarbazepine                      3        5.6                 1.1 (0.4 to 3.7)       0.8 (0.2 to 3.2)
   Pregabalin                         28       5.0                 1.0 (0.6 to 1.6)       0.6 (0.4 to 1.0)
   Topiramate                         7        4.1                 0.8 (0.4 to 1.8)       0.8 (0.4 to 1.9)
   **Valproic acid**                  **50**   **13.5**            **2.7 (1.9 to 4.0)**   **2.7 (1.8 to 4.0)**
  Pervasive developmental disorders                                                       
   Lamotrigine                        11       1.1                                         
   Carbamazepine                      3        1.6                 1.5 (0.4 to 5.4)       1.3 (0.3 to 5.0)
   Clonazepam                         8        1.4                 1.4 (0.5 to 3.4)       0.8 (0.3 to 2.1)
   Gabapentin                         3        2.3                 2.2 (0.6 to 7.9)       1.8 (0.4 to 7.0)
   Levetiracetam                      4        1.8                 1.8 (0.6 to 5.5)       1.6 (0.5 to 5.4)
   Oxcarbazepine                      1        1.9                 1.8 (0.2 to 13.6)      2.0 (0.3 to 13.8)
   Pregabalin                         7        1.2                 1.2 (0.5 to 3.1)       1.1 (0.4 to 3.0)
   Topiramate                         1        0.6                 0.6 (0.1 to 4.3)       0.3 (0.0 to 4.9)
   **Valproic acid**                  **17**   **4.5**             **4.3 (2.0 to 9.1)**   **4.4 (2.1 to 9.3)**
  Mental retardation                                                                      
   Lamotrigine                        15       1.4                                         
   Carbamazepine                      2        1.1                 0.7 (0.2 to 3.2)       0.6 (0.1 to 2.9)
   Clonazepam                         3        0.5                 0.4 (0.1 to 1.3)       0.3 (0.1 to 1.2)
   Gabapentin                         0        0.0                 N/A                    N/A
   Levetiracetam                      1        0.5                 0.3 (0.0 to 2.4)       0.3 (0.0 to 2.5)
   Oxcarbazepine                      0        0.0                 N/A                    N/A
   Pregabalin                         7        1.2                 0.9 (0.4 to 2.1)       0.6 (0.2 to 1.8)
   Topiramate                         2        1.2                 0.8 (0.2 to 3.5)       0.5 (0.1 to 3.3)
   **Valproic acid**                  **15**   **4.0**             **2.8 (1.3 to 5.6)**   **3.1 (1.5 to 6.2)**
  Visits to a speech therapist                                                            
   Lamotrigine                        157      15.2                                        
   Carbamazepine                      31       16.7                1.1 (0.8 to 1.6)       0.9 (0.6 to 1.4)
   Clonazepam                         97       17.7                1.2 (0.9 to 1.5)       0.8 (0.6 to 1.0)
   Gabapentin                         11       8.5                 0.6 (0.3 to 1.0)       0.7 (0.4 to 1.2)
   Levetiracetam                      22       10.2                0.7 (0.4 to 1.1)       0.7 (0.5 to 1.1)
   Oxcarbazepine                      13       24.6                1.6 (0.9 to 2.9)       1.3 (0.7 to 2.5)
   **Pregabalin**                     **61**   **11.0**            **0.7 (0.5 to 1.0)**   **0.7 (0.5 to 1.0)**
   Topiramate                         33       19.4                1.3 (0.9 to 1.9)       1.2 (0.8 to 1.8)
   **Valproic acid**                  **93**   **25.1**            **1.7 (1.3 to 2.1)**   **1.5 (1.1 to 1.9)**

Lines marked in bold correspond to HRs for which the 95% CI does not include 1.

AED, antiepileptic drug; CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio; N/A, not applicable.

Sensitivity analyses {#s3-2}
--------------------

In the first sensitivity analysis restricting the study population to women considered to be treated for epilepsy, only results related to carbamazepine, levetiracetam and valproic acid are reported. The number of women considered to be treated for epilepsy and exposed to monotherapy with each of the other AEDs was \<100. Baseline patient characteristics and absolute standardised differences are available in [online supplementary table 3](#SP1){ref-type="supplementary-material"} and [online supplementary figure 1](#SP1){ref-type="supplementary-material"}, respectively. Compared with lamotrigine, prenatal exposure to levetiracetam was not found to be associated with any of the four outcomes investigated and prenatal exposure to valproic acid was associated with all four outcomes, which is in line with the results of the main analysis. Results were different from the main analysis for the association between carbamazepine and the risk of visits to a speech therapist (HR=0.2, 95% CI (0.1 to 0.7)) ([table 3](#T3){ref-type="table"}).

###### 

Number of events, crude event rates (per 1000), crude IRRs and adjusted HRs for the four outcomes and each of the AEDs studied---study population limited to women considered to be treated for epilepsy

                                      Events   Crude event rates   IRR                     HR\* (95% CI)           HR† (95% CI)
  ----------------------------------- -------- ------------------- ----------------------- ----------------------- -----------------------
  Neurodevelopmental disorders                                                                                     
   Lamotrigine                        32       4.2                                                                 
   Carbamazepine‡                     1        1.5                 0.4 (0.0 to 2.7)        0.2 (0.0 to 2.7)        0.2 (0.0 to 2.7)
   Levetiracetam                      8        3.7                 0.9 (0.4 to 1.9)        0.8 (0.4 to 1.8)        0.8 (0.4 to 1.8)
   **Valproic acid**                  **50**   **13.5**            **3.2 (2.0 to 5.0)**    **3.2 (2.0 to 4.9)**    **3.5 (2.3 to 5.4)**
  Pervasive developmental disorders                                                                                
   Lamotrigine                        7        0.9                                                                 
   Carbamazepine‡                     0        0.0                 N/A                     N/A                     N/A
   Levetiracetam                      4        1.8                 2.0 (0.6 to 6.8)        1.8 (0.5 to 6.6)        1.8 (0.5 to 6.6)
   **Valproic acid**                  **17**   **4.5**             **4.9 (2.0 to 11.8)**   **4.9 (2.0 to 11.8)**   **4.7 (1.9 to 11.4)**
  Mental retardation                                                                                               
   Lamotrigine                        10       1.3                                                                 
   Carbamazepine‡                     0        0.0                 N/A                     N/A                     N/A
   Levetiracetam                      1        0.5                 0.3 (0.0 to 2.7)        0.4 (0.1 to 2.9)        0.4 (0.1 to 2.9)
   **Valproic acid**                  **15**   **4.0**             **3.0 (1.4 to 6.7)**    **3.1 (1.4 to 7.0)**    **4.0 (1.9 to 8.6)**
  Visits to a speech therapist                                                                                     
   Lamotrigine                        122      16.2                                                                
   **Carbamazepine‡**                 **4**    **6.1**             **0.4 (0.1 to 1.0)**    **0.2 (0.1 to 0.7)**    **0.2 (0.1 to 0.7)**
   Levetiracetam                      22       10.2                0.6 (0.4 to 1.0)        0.7 (0.4 to 1.1)        0.7 (0.4 to 1.1)
   **Valproic acid**                  **93**   **25.1**            **1.6 (1.2 to 2.0)**    **1.4 (1.1 to 1.8)**    **1.5 (1.1 to 1.9)**

Lines marked in bold correspond to HRs for which the 95% CI does not include 1.

\*Adjusted for all covariates except hospitalisation for epilepsy during pregnancy.

†Adjusted for all covariates including hospitalisation for epilepsy during pregnancy.

‡No possible adjustment for the proxy for alcohol.

AED, antiepileptic drug; CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio; N/A, not applicable.

The results of the second (see [online supplementary figure 2](#SP1){ref-type="supplementary-material"} for standardised differences) and third sensitivity analyses were comparable to those of the main analysis (see [online supplementary table 4](#SP1){ref-type="supplementary-material"} and [online supplementary table 5](#SP1){ref-type="supplementary-material"}, respectively).

Dose {#s3-3}
----

Baseline patient characteristics according to the dose of valproic acid dispensed during pregnancy are reported in [online supplementary table 6](#SP1){ref-type="supplementary-material"}. A dose-response relationship was observed for the association between prenatal exposure to valproic acid and the risks of visits to a speech therapist (\<700 mg: HR=0.6, 95% CI (0.3 to 1.0); 700--1500 mg: HR=1.6 (1.2 to 2.1); ≥1500 mg: HR=2.6 (1.7 to 4.0)) and neurodevelopmental disorders (\<700 mg: HR=1.3 (0.6 to 2.8); 700--1500 mg: HR=2.1 (1.3 to 3.5); ≥1500 mg: HR=7.0 (4.3 to 11.5)), including pervasive developmental disorders (\<700 mg: HR=2.2 (0.5 to 8.5); 700--1500 mg: HR=2.7 (1.0 to 7.1); ≥1500 mg: HR=14.7 (6.2 to 34.7)). The highest HR of mental retardation was also observed for the highest mean daily dose (≥1500 mg: HR=7.3 (3.0 to 17.7)). Comparable results were observed when the study population was limited to women considered to be treated for epilepsy ([table 4](#T4){ref-type="table"}).

###### 

Number of events, crude event rates (per 1000), crude IRRs and adjusted HRs for the four outcomes according to the dose of valproic acid dispensed during pregnancy---main analysis and sensitivity analysis restricted to women considered to be treated for epilepsy

                                      Events     Crude event rates   Main analysis        Women with epilepsy                                                                  
  ----------------------------------- ---------- ------------------- -------------------- --------------------- -------------------- -------------------- -------------------- -------------------
  Neurodevelopmental disorders        \<700 mg   7                   6.3                  1.3 (0.6 to 2.8)      1.3 (0.6 to 2.8)     1.5 (0.7 to 3.4)     1.6 (0.7 to 3.6)     1.6 (0.7 to 3.6)
  700--1500 mg                        23         11.5                2.3 (1.4 to 3.8)     2.1 (1.3 to 3.5)      2.7 (1.6 to 4.6)     2.5 (1.5 to 4.3)     2.7 (1.6 to 4.6)     
  ≥1500 mg                            20         33.5                6.8 (4.1 to 11.5)    7.0 (4.3 to 11.5)     7.9 (4.5 to 13.8)    8.6 (5.1 to 14.5)    8.7 (5.2 to 14.6)    
  Pervasive developmental disorders   \<700 mg   2                   1.8                  1.7 (0.4 to 7.6)      2.2 (0.5 to 8.5)     1.9 (0.4 to 9.3)     2.9 (0.7 to 11.6)    2.7 (0.7 to 11.4)
  700--1500 mg                        7          3.4                 3.3 (1.3 to 8.4)     2.7 (1.0 to 7.1)      3.7 (1.3 to 10.7)    3.1 (1.1 to 9.0)     3.0 (1.0 to 8.9)     
  ≥1500 mg                            8          12.8                12.2 (4.9 to 30.4)   14.7 (6.2 to 34.7)    14.0 (5.1 to 38.5)   17.0 (6.5 to 44.6)   15.4 (5.7 to 41.1)   
  Mental retardation                  \<700 mg   5                   4.4                  3.1 (1.1 to 8.5)      1.5 (0.4 to 5.9)     3.4 (1.2 to 9.9)     1.8 (0.4 to 7.0)     1.6 (0.4 to 6.7)
  700--1500 mg                        5          2.5                 1.7 (0.6 to 4.7)     1.8 (0.7 to 4.9)      1.9 (0.6 to 5.5)     1.9 (0.7 to 5.7)     2.6 (1.0 to 6.7)     
  ≥1500 mg                            5          7.9                 5.5 (2.0 to 15.2)    7.3 (3.0 to 17.7)     6.0 (2.1 to 17.6)    7.1 (2.7 to 18.7)    8.4 (3.4 to 20.4)    
  Visits to a speech therapist        \<700 mg   13                  11.6                 0.8 (0.4 to 1.3)      0.6 (0.3 to 1.0)     0.7 (0.4 to 1.3)     0.6 (0.3 to 1.0)     0.5 (0.3 to 0.9)
  700--1500 mg                        54         27.3                1.8 (1.3 to 2.5)     1.6 (1.2 to 2.1)      1.7 (1.2 to 2.3)     1.5 (1.1 to 2.0)     1.5 (1.1 to 2.1)     
  ≥1500 mg                            26         43.4                2.9 (1.9 to 4.3)     2.6 (1.7 to 4.0)      2.7 (1.8 to 4.1)     2.6 (1.7 to 4.0)     2.7 (1.8 to 4.1)     

\*Adjusted for all covariates except hospitalisation for epilepsy during pregnancy.

†Adjusted for all covariates including hospitalisation for epilepsy during pregnancy.

CI, confidence interval; HR, hazard ratio; IRR, incidence rate ratio.

Discussion {#s4}
==========

Main findings {#s4-1}
-------------

In this nationwide observational study based on the French healthcare databases, prenatal exposures to levetiracetam, pregabalin, oxcarbazepine, topiramate, gabapentin, clonazepam and carbamazepine were not associated with an increased risk of any of the early neurodevelopmental outcomes investigated compared with lamotrigine. The decreased risk of visits to a speech therapist observed with carbamazepine when the population was restricted to women with epilepsy may be a chance finding. This association is based on only four children and carbamazepine was associated with reduced verbal abilities in one study.[@R19] Prenatal exposure to valproic acid was found to be associated with increased risks of all neurodevelopmental outcomes investigated compared with lamotrigine, ranging from pervasive mental disorders to possible communication-related disorders. A dose-response relationship was observed for most of these outcomes.

Comparison with previous studies {#s4-2}
--------------------------------

Prenatal exposure to lamotrigine has been mostly shown not to be associated with poorer neurodevelopmental outcomes, although limited data are available, with no dose-response relationship.[@R6] Only two studies have shown that prenatal exposure to lamotrigine was associated with impaired specific cognitive skills[@R20] and parental concerns about autistic traits and sentence skills.[@R21]

The results of the present study concerning valproic acid, carbamazepine, levetiracetam and topiramate are consistent with those of previous studies. Prenatal exposure to valproic acid has been associated with poorer cognitive outcomes[@R19] and particularly poorer executive functions and memory abilities[@R23] compared with lamotrigine. Children prenatally exposed to valproic acid also show impaired adaptive behaviour[@R25] and school performance[@R27] compared with lamotrigine-exposed children. Impaired language skills[@R28] and autism spectrum disorder have been reported to be more frequent among children exposed to valproic acid than among unexposed children.[@R29] A dose-response relationship has also been observed for most of these outcomes.[@R19]

Few studies have directly compared prenatal exposure with carbamazepine versus lamotrigine and these studies did not find any differences in terms of cognitive development[@R22] and adaptive behaviour.[@R26] Data concerning levetiracetam and topiramate are more limited and no direct comparison with lamotrigine has been published. No increased risk of neurodevelopmental outcomes was found among levetiracetam-exposed children compared with unexposed children[@R32] and, although prenatal exposure to topiramate was associated with poorer neurodevelopmental outcomes in one study,[@R35] this association was not confirmed by a larger study.[@R33] Little or no information is available concerning the other AEDs, particularly clonazepam, oxcarbazepine, gabapentin and pregabalin.[@R29]

Strengths {#s4-3}
---------

This nationwide cohort study based on the French healthcare database is the largest study to date to assess the association between AED exposure during pregnancy and neurodevelopmental outcomes in the offspring. This study investigated a wide range of AEDs, including some drugs for which little or no information is available in the literature. The strengths of this study also include the use of propensity score methods to mitigate confounding, as well as the advantages of the French healthcare databases, such as the independence between ascertainment of medication and outcomes, the absence of recall bias, and the possibility to study the dose-response relationship, which is a key concept in terms of teratogenicity.[@R33]

Limitations {#s4-4}
-----------

Exposure misclassification constitutes a first limitation. Exposure assessment was based on pharmacy claims, which do not indicate whether the medication is actually taken. Exposure misclassification is more likely for AED classes that are often discontinued before conception.[@R37] However, the results of the sensitivity analysis regarding exposure measurement suggest that this bias is likely minimal.

Although we used an active-comparator design, residual confounding by unmeasured or insufficiently well-measured covariates cannot be excluded. For instance, maternal education and IQ were not available in the databases. Data related to the father could not be linked to the child, not allowing any adjustment for paternal characteristics. Lifestyle factors such as alcohol intake and smoking could also not be exhaustively assessed.

As some AEDs can be prescribed to treat conditions other than epilepsy, the analyses were replicated in a population restricted to women considered to be treated for epilepsy, providing comparable results to those of the main analysis. However, the indication for which an AED is prescribed was not directly available in the databases. We therefore used LTD diagnoses, hospital diagnoses and specific drug reimbursements to identify women with epilepsy. Some studies,[@R34] unlike other studies,[@R19] have also reported an association between the severity of maternal epilepsy, particularly seizure type and frequency, and poorer developmental outcomes in the child. As this confounder was not available in the databases, we considered at least one admission to hospital for epilepsy during pregnancy to be a proxy for epilepsy severity. Similar results were observed whether or not this proxy was included in the propensity score.

Outcome misclassification also cannot be ruled out, as the diagnosis codes used to identify neurodevelopmental outcomes have not been externally validated. However, the PMSI database is used for planning and funding purposes and is subject to coding quality control, and LTD registration, which is requested by the patient's general practitioner, must be validated by a medical consultant of the beneficiary's health insurance scheme. In addition, as hospital discharge and LTD diagnoses were used to define outcomes, children not reaching diagnostic thresholds but still having some evidence of impairment were not considered to have experienced the outcomes of interest.[@R40] Moreover, some of the outcomes studied may not have been exhaustively assessed, as data related to a large share of medical and social welfare services are not available in the French healthcare databases. Results related to visits to a speech therapist must also be interpreted with caution, as a visit to a speech therapist does not necessarily imply pathology. Speech therapists can also be consulted for various medical reasons, and access to speech therapists is associated with socioeconomic status.[@R41] Furthermore, because the study outcomes were limited to three subtypes of neurodevelopmental disorders (pervasive developmental disorders, mental retardation and visits to a speech therapist as a proxy for communication-related disorders), no conclusion can be drawn concerning all of the other subtypes of neurodevelopmental disorders.

The short follow-up period constitutes another limitation: the median and maximum lengths of follow-up were 3.7 and 6 years, respectively. In particular, a diagnosis of autism spectrum disorders is considered to be stable at age 2[@R42] and is made at an average age of 3 years and 5 months in France,[@R43] but speech therapy is more frequent among school-aged children. Therefore, only early diagnoses, probably corresponding to more severe disorders, were identified. This is especially true for mental retardation: although severe and profound mental retardation can be diagnosed before 3 years of age, moderate mental retardation cannot be diagnosed before 4 or 5 years of age.[@R44] Further assessment of children at older developmental stages would be useful to study a broader range of neurodevelopmental disorders. Except clonazepam for which French health authorities took measures to limit off-label use in November 2011,[@R45] lengths of follow-up were quite comparable across all AEDs. Children exposed to second-generation AEDs had only slightly shorter follow-ups than children exposed to first-generation AEDs, which should not have influenced the results of this study.

Conclusion {#s5}
==========

Despite the limitations inherent to healthcare claims databases, this study, based on 9034 exposed children, confirms that valproic acid is associated with an increased risk of various neurodevelopmental outcomes compared with lamotrigine, with a dose-response relationship, while no association was observed for the other AEDs including carbamazepine, levetiracetam or topiramate. However, this study needs to be replicated with a longer follow-up period.
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